Bayer Pharmaceuticals
Bayer Pharmaceuticals, the pharma division of Bayer AG, develops and commercializes prescription drugs across cardiology, oncology, women's health, ophthalmology, and rare diseases in 93 countries. It operates a 40-program pipeline spanning small molecules, biologics, cell and gene therapies, and AI-augmented discovery.
- Company typePublic
- Founded1863
- HeadquartersBerlin, Germany
- Headcount5,001–10,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Bayer Pharmaceuticals does
Bayer Pharmaceuticals is the pharmaceutical division of Bayer AG, a publicly listed German multinational (Frankfurt Stock Exchange: BAYZN) headquartered in Leverkusen. It develops, manufactures, and commercializes prescription pharmaceuticals across cardiology, oncology, women's health, ophthalmology, hematology, and rare diseases, serving patients in 93 countries through direct sales, healthcare distribution networks, and pharmacy channels. Its revenue model is anchored by global product sales, supplemented by licensing, partnership, and milestone-based income from more than 30 active collaborations with academic institutions, biotechnology companies, and technology partners.
The division's technology portfolio is broad and modality-diversified, spanning approximately 55% small molecules and 45% biologics and advanced therapies across 40 active programs (31 in clinical development as of January 2026). Core platforms include precision medicine, cell and gene therapy (gene therapy, cell therapy, gene editing), AAV therapeutics, PROTACs, RNA-targeting small molecules, targeted alpha therapy, chemoproteomics, immuno-oncology, and diagnostic imaging. AI is integrated across the value chain — from target identification and biomarker discovery to clinical trial optimization and imaging analysis — with senior AI/ML and biologics leadership embedded in the organization. Notable assets include the reference-listed drug Vitrakvi (larotrectinib) for TRK fusion cancers and sevabertinib, an ERBB2-mutant NSCLC candidate under FDA Priority Review arising from the Broad Institute collaboration.
Bayer Pharmaceuticals goes to market through enterprise field sales targeting healthcare institutions and specialty pharmacies, supported by healthcare-professional engagement, scientific publications, medical conferences, and patient information platforms. Recent strategic activity has centered on partnerships for precision oncology (Broad Institute, Lung Cancer Research Foundation), the 2022 acquisition of Vividion Therapeutics for covalent-binding drug discovery, and R&D expansion in Beijing (2024) to participate in China's strategic medical device and pharmaceutical ecosystem. Bayer AG's board-level oversight includes Bill Anderson, Judith Hartmann, Stefan Oelrich, Heike Prinz, Rodrigo Santos, and Julio Triana, with Dieter Weinand identified as president and CEO in the division's leadership data.
Bayer Pharmaceuticals firmographics
Firmographics- Name
- Bayer Pharmaceuticals
- Legal name
- Bayer AG
- Website
- https://pharma.bayer.com
- Company type
- Public
- Founded year
- 1863
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Bayer Pharmaceuticals, the pharma division of Bayer AG, develops and commercializes prescription drugs across cardiology, oncology, women's health, ophthalmology, and rare diseases in 93 countries. It operates a 40-program pipeline spanning small molecules, biologics, cell and gene therapies, and AI-augmented discovery.
- Ownership category
- akta.pro rank
Bayer Pharmaceuticals industry classification
Industry- Product category
- Prescription Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (32541), Medical Equipment and Supplies Manufacturing (33911)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Oncology Specialty Pharmaceuticals (HLAIACAA), Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
Keywords
Where Bayer Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Berlin
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Bayer Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Bayer Pharmaceuticals generates revenue through the sale of innovative prescription pharmaceuticals across therapeutic areas including cardiology, oncology, women's health, hematology, and rare diseases. The company maintains a robust pipeline with 40 active programs and serves patients in 93 countries.
- Licensing and Partnership Revenue: Strategic partnerships and collaborations that may include licensing agreements, co-development arrangements, and milestone payments. Bayer maintains more than 30 active partnerships with academic institutions, biotechnology companies, and technology partners.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Bayer Pharmaceuticals product offering
Product offeringCore offering
Bayer Pharmaceuticals develops, manufactures, and commercializes prescription medicines across five therapeutic areas: cardiovascular, oncology, women's health, ophthalmology, and rare disease. Its portfolio is balanced between small molecules (~55%) and biologics/advanced therapies (~45%), with 40 active pipeline programs and a stated focus on precision medicine, cell and gene therapy, and targeted oncology.
Product overview
Bayer Pharmaceuticals is a global pharmaceutical company with 148 years of experience serving 93 countries. The company operates a diversified portfolio centered around a robust clinical pipeline of 40 active programs (as of January 2026), with approximately 55% small molecules and 45% biologics and advanced therapies. The core offering encompasses multiple therapeutic areas including Oncology (treatments for gastrointestinal stromal tumor, breast cancer, kidney cancer, liver cancer, prostate cancer, TRK fusion cancer, thyroid cancer, NSCLC), Cardiovascular and Renal Health (heart attack, thrombosis, stroke, atrial fibrillation, heart failure, high blood pressure, chronic kidney disease), Women's Health (contraception, menopause, endometriosis, heavy menstrual bleeding, acne), Eye Conditions (age-related macular degeneration, diabetic macular edema), Hematology, and Healthy Aging. Bayer's innovation platform includes Cell and Gene Therapy (gene therapy, cell therapy, gene editing), Radiology and Diagnostics, AAV Therapeutics, Stem Cell Research, PROTAC Technology, RNA-targeting Small Molecules, and Diagnostic Imaging. The company leverages AI across its pharmaceutical value chain for accelerated drug discovery and development.
Differentiator
Problem solved
Functional benefit
Brands
- Vitrakvi: Larotrectinib capsules for treatment of solid tumors with NTRK gene fusion, reference listed drug for which Bayer Healthcare Pharmaceuticals holds the original approval.
Products and services
- Pharmaceuticals Portfolio
- Oncology Therapeutics
- Vitrakvi (Larotrectinib)
- Women's Health Treatments
- Cardiovascular and Renal Treatments
- Ophthalmology Treatments
- Rare Disease Treatments
- Cell and Gene Therapy Platform
- Radiology and Diagnostic Imaging Agents
Quantifiable outcome
- 40 active programs in pipeline as of January 2026
- +3 more outcomes
Companies that use Bayer Pharmaceuticals
Customer profileNamed customers5 records
Segments5 records
Ideal customer profiles3 records
Bayer Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability8 records
Feature9 records
Bayer Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and regional.
- Lung Cancer Research FoundationcoreLung Cancer Research Foundation awarded grants including collaboration with Bayer Pharmaceuticals on HER2-mutant lung cancer research. The partnership is part of a $5.2 million grant cycle with 21 grant awards, contributing to the organization's active research portfolio exceeding $21 million.
- Broad InstitutecoreScientists at the Broad Institute and Bayer Pharmaceuticals developed drug candidate sevabertinib aimed at treating non-small cell lung cancers with ERBB2 mutations. The drug is currently under Priority Review at the FDA, with potential approval based on ongoing clinical trial results. This represents a significant academic-industry collaboration in targeted oncology.
- Beijing Medical Device IndustryregionalBayer Pharmaceuticals established R&D facilities in Beijing as part of China's strategic medical device and pharmaceutical ecosystem. Beijing has designated its medical device industry as a strategic priority under a 2024-2026 Action Plan, targeting growth to over RMB 50 billion (US$7.4 billion).
Scale indicators5 records
Recent moves6 records
Expansion highlights6 records
Bayer Pharmaceuticals competitors and assessment
Company assessmentDirect peers
- Sanofi: European-headquartered multinational with overlapping specialty care, rare disease (Genzyme), and oncology ambitions. Comparable scale and similar global distribution footprint.
- Merck & Co. (MSD): Major oncology competitor (Keytruda) and cardiovascular player with similar global commercial scale. Comparable in pipeline diversification across specialty and primary care.
- Roche: Global pharma leader with deep oncology, diagnostics, and specialty care portfolios. Competes directly with Bayer in oncology and women's health, and overlaps in diagnostic imaging/diagnostics integration.
- Pfizer: Global branded pharmaceutical company with comparable diversified therapeutic areas (oncology, cardiovascular, rare disease) and similar biologics/small-molecule mix. Direct competitor in cardiology and oncology markets where both companies operate.
- Novartis: Major Swiss multinational with overlapping franchises in cardiovascular, oncology, and cell/gene therapy (Kymriah, Zolgensma). Comparable pipeline scale and innovation model make Novartis one of the closest comparables.
- AstraZeneca: Direct competitor in oncology (NSCLC, breast, prostate) and cardiovascular disease, with similar emphasis on targeted therapies, antibody-drug conjugates, and AI-enabled clinical development.
- Bristol-Myers Squibb: Specialty pharma competitor in cardiovascular (Eliquis competing with Xarelto) and oncology (immuno-oncology overlaps Bayer's stated strategy). Directly comparable R&D intensity.
- GSK: UK-based pharma with established vaccines, specialty, and oncology presence. Competes with Bayer in women's health and select oncology indications; similar enterprise-scale and pipeline breadth.
Broad incumbents
- Eli Lilly: Large incumbent pharma expanding aggressively in oncology and cardiometabolic; competes with Bayer in diabetes/obesity adjacency and precision oncology. Comparable pipeline diversification.
- Johnson & Johnson Innovative Medicine: Diversified pharma division with strong oncology and cardiovascular franchises. Comparable global scale and innovation model, though broader portfolio includes medtech and consumer.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Bayer Pharmaceuticals social profiles
Digital presenceBayer Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bayer Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles12 records
Bayer Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bayer Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bayer Pharmaceuticals
What does Bayer Pharmaceuticals do?
Bayer Pharmaceuticals develops, manufactures, and commercializes prescription medicines across five therapeutic areas: cardiovascular, oncology, women's health, ophthalmology, and rare disease. Its portfolio is balanced between small molecules (~55%) and biologics/advanced therapies (~45%), with 40 active pipeline programs and a stated focus on precision medicine, cell and gene therapy, and targeted oncology.
Is Bayer Pharmaceuticals a public or private company?
Bayer Pharmaceuticals is a public company. It is classified as public and is currently operating.
When was Bayer Pharmaceuticals founded?
Bayer Pharmaceuticals was founded in 1863. It employs 5,001 to 10,000 people.
Where is Bayer Pharmaceuticals based?
Bayer Pharmaceuticals is headquartered in Berlin, Germany, in the Europe region.
How does Bayer Pharmaceuticals make money?
Two revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are licensing and Partnership Revenue.
Who are Bayer Pharmaceuticals's main competitors?
Direct peers on record are Sanofi, Merck & Co. (MSD), Roche, Pfizer, Novartis, AstraZeneca, Bristol-Myers Squibb and GSK. Broad incumbents are Eli Lilly and Johnson & Johnson Innovative Medicine.
Does Bayer Pharmaceuticals have an API?
No public API is recorded for Bayer Pharmaceuticals.
What industry is Bayer Pharmaceuticals in?
Bayer Pharmaceuticals's product category is Prescription Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAA, Oncology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.